T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cytokines are chemicals that are naturally made by your body. Certain cytokine levels are changed in the blood of patients who develop allergies and/or asthma. Cytokine levels may also be changed in some individuals who are overweight or obese. The purpose of this study is to determine if certain cytokine levels differ based on a person's weight and whether or not they have allergies or asthma. Information gathered in this study will be compared to information gathered from subjects who have participated in another similar study for patients who have allergies and/or asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Cell Response to Stimuli

NCT00397280

Inflammation

RECRUITING

Immunization Against Tumor Cells in Sezary Syndrome

NCT00099593

Cutaneous T-cell Lymphoma Sezary Syndrome

COMPLETED PHASE2

The COX-2 Gene and the Immune System

NCT01678222

Allergic Inflammation Asthma

COMPLETED

Effect of Denileukin Diftitox on Immune System in CTCL Patients

NCT00254332

Cutaneous T-cell Lymphoma Sezary Syndrome Mycosis Fungoides

COMPLETED

The Effects of Upper Airway and Digestive Tract Tumors on the Immune System

NCT00001603

Esophageal Neoplasm Head and Neck Neoplasm Laryngeal Neoplasm +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aims of this study are to:

1. Characterize the relationship between BMI and Th2 skewing in non-atopic adult subjects.
2. Compare these results to those previously obtained from atopic adult subjects It is expected that the results of this study will demonstrate enhanced Th2 skewing in overweight and obese atopic subjects as compared to non-atopic subjects. It is further anticipated that the results of this study will be used as preliminary data to generate an NIH grant application exploring the link between obesity and atopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal BMI

Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.

No interventions assigned to this group

Overweight BMI

Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.

No interventions assigned to this group

Obese BMI

Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults aged 18 to 50 years
* pre-bronchodilator FEV1 \> 80% predicted with no evidence of reversibility following administration of bronchodilator
* no history of allergies

Exclusion Criteria

* medical history consistent with atopy and/or asthma
* any positive response to allergy skin testing for inhalant allergens (defined as a wheal \> 3 mm larger than the negative control)
* a pre-bronchodilator FEV1 \< 80% predicted
* \> 12% reversibility in FEV1 following administration of a bronchodilator
* any history of significant chronic illness
* history of respiratory infection within the past 2 weeks
* any use of prescription medications other than oral contraceptives or thyroid hormone replacement within the past 2 months
* use of any investigational medication within the past month

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes